DelveInsight’s “Brain Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Brain Cancer, historical and forecasted epidemiology as well as the Brain Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Brain Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Brain Cancer Market Forecast
Some of the key facts of the Brain Cancer Market Report:
- The Brain Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In August 2023, Immunomic Therapeutics announced dosing of the firstpatient in its Phase I clinical trial evaluating ITI-1001, a plasmid DNA (pDNA)vaccine, for the treatment of GBM, top-line data is expected in the secondquarter of 2025.
- In September 2023, Orbus Therapeutics announced that the first patienthas been enrolled in its Phase Ib study combining temozolomide and eflornithine in patients newly diagnosed with GBM.
- As per the American Society of Clinical Oncology (ASCO), primary brain tumors make up 85–90% of all central nervous system (CNS) tumors. It is projected that in 2023, around 24,810 adults in the United States (comprising 14,280 men and 10,530 women) will receive a diagnosis of primary cancerous tumors affecting the brain and spinal cord.
- As stated by Brain Tumor UK, approximately 70–80% of primary brain tumors are categorized as High-Grade Gliomas. These tumors are most commonly observed in individuals aged between 46 and 50, with a higher incidence in men than in women.
- Within the seven major markets (7MM), the highest number of instances was identified for Grade IV glioma, totaling almost 33,000 cases in 2022. This was succeeded by Grade II and Grade III gliomas.
- Key Brain Cancer Companies: Orbus Therapeutics, Eisai, Immunomic Therapeutics, Servier, Medicenna Therapeutics, NatureWise Biotech, medac GmbH, Crown Bioscience, DUSA Pharmaceuticals, Inc., Bayer, Ono Pharmaceutical Co. Ltd, NewLink Genetics Corporation, TransMolecular, Genzyme, Eli Lilly and Company, Direct Therapeutics, InSightec, Neurobiological Technologies, Monte Verde SA, Pfizer, and others
- Key Brain Cancer Therapies: Eflornithine + Lomustine, LENVIMA + KEYTRUDA, ITI-1000, Vorasidenib (AG-881), MDNA55, NBM-BMX Capsule, Gliolan, Karenitecin (BNP1350), Tumor fluorescence, Magnevist (SH L 451A), Nivolumab, Indoximod, 131I-TM-601, 89Zr-GC1008, abemaciclib, DTI-015, Doxorubicin, hCRF, Temozolomide, Palbociclib, and others
- The Brain Cancer epidemiology based on gender analyzed that Brain Tumors is slightly more common in men as compared to women
- The Brain Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Brain Cancer pipeline products will significantly revolutionize the Brain Cancer market dynamics.
Brain Cancer Overview
Brain cancer refers to the abnormal and uncontrolled growth of cells in the brain, leading to the formation of a tumor. There are various types of brain tumors, and they can be either benign (non-cancerous) or malignant (cancerous). Malignant tumors, also known as brain cancer, have the potential to invade nearby tissues and spread to other parts of the brain or the central nervous system.
Get a Free sample for the Brain Cancer Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/brain-cancer-market
Brain Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Brain Cancer Epidemiology Segmentation:
The Brain Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Brain Cancer
- Prevalent Cases of Brain Cancer by severity
- Gender-specific Prevalence of Brain Cancer
- Diagnosed Cases of Episodic and Chronic Brain Cancer
Download the report to understand which factors are driving Brain Cancer epidemiology trends @ Brain Cancer Epidemiology Forecast
Brain Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Brain Cancer market or expected to get launched during the study period. The analysis covers Brain Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Brain Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Brain Cancer Therapies and Key Companies
- Eflornithine + Lomustine: Orbus Therapeutics
- LENVIMA + KEYTRUDA: Eisai
- ITI-1000: Immunomic Therapeutics
- Vorasidenib (AG-881): Servier
- MDNA55: Medicenna Therapeutics
- NBM-BMX Capsule: NatureWise Biotech
- Gliolan: medac GmbH
- Karenitecin (BNP1350): Crown Bioscience
- Tumor fluorescence: DUSA Pharmaceuticals, Inc.
- Magnevist (SH L 451A): Bayer
- Nivolumab: Ono Pharmaceutical Co. Ltd
- Indoximod: NewLink Genetics Corporation
- 131I-TM-601: TransMolecular
- 89Zr-GC1008: Genzyme
- abemaciclib: Eli Lilly and Company
- DTI-015: Direct Therapeutics
- Doxorubicin: InSightec
- hCRF: Neurobiological Technologies
- Temozolomide: Monte Verde SA
- Palbociclib: Pfizer
Discover more about therapies set to grab major Brain Cancer market share @ Brain Cancer Treatment Landscape
Brain Cancer Market Strengths
- Rise in brain cancer market is attributed to several factors such as aging population, evolving research, more diagnostic tests, developing surgical approaches, improved radiotherapy techniques and novel systemic therapies.
- Various intratumoral therapies are under development which will help in overcoming the challenge of delivering the drugs across the blood-brain barrier and provide better treatment outcomes.
Brain Cancer Market Opportunities
- Due to lack of competitors in anaplastic astrocytoma, there is a substantial market opportunity for key players to develop anaplastic tumor targeting therapies.
- Numerous failed clinical trials suggest combination therapies will likely be the most promising method of GBM treatment, and emphasis should be applied to drug design and pharmacokinetic properties
Scope of the Brain Cancer Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Brain Cancer Companies: Orbus Therapeutics, Eisai, Immunomic Therapeutics, Servier, Medicenna Therapeutics, NatureWise Biotech, medac GmbH, Crown Bioscience, DUSA Pharmaceuticals, Inc., Bayer, Ono Pharmaceutical Co. Ltd, NewLink Genetics Corporation, TransMolecular, Genzyme, Eli Lilly and Company, Direct Therapeutics, InSightec, Neurobiological Technologies, Monte Verde SA, Pfizer, and others
- Key Brain Cancer Therapies: Eflornithine + Lomustine, LENVIMA + KEYTRUDA, ITI-1000, Vorasidenib (AG-881), MDNA55, NBM-BMX Capsule, Gliolan, Karenitecin (BNP1350), Tumor fluorescence, Magnevist (SH L 451A), Nivolumab, Indoximod, 131I-TM-601, 89Zr-GC1008, abemaciclib, DTI-015, Doxorubicin, hCRF, Temozolomide, Palbociclib, and others
- Brain Cancer Therapeutic Assessment: Brain Cancer current marketed and Brain Cancer emerging therapies
- Brain Cancer Market Dynamics: Brain Cancer market drivers and Brain Cancer market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Brain Cancer Unmet Needs, KOL’s views, Analyst’s views, Brain Cancer Market Access and Reimbursement
To know more about Brain Cancer companies working in the treatment market, visit @ Brain Cancer Clinical Trials and Therapeutic Assessment
Table of Contents
1. Brain Cancer Market Report Introduction
2. Executive Summary for Brain Cancer
3. SWOT analysis of Brain Cancer
4. Brain Cancer Patient Share (%) Overview at a Glance
5. Brain Cancer Market Overview at a Glance
6. Brain Cancer Disease Background and Overview
7. Brain Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Brain Cancer
9. Brain Cancer Current Treatment and Medical Practices
10. Brain Cancer Unmet Needs
11. Brain Cancer Emerging Therapies
12. Brain Cancer Market Outlook
13. Country-Wise Brain Cancer Market Analysis (2019–2032)
14. Brain Cancer Market Access and Reimbursement of Therapies
15. Brain Cancer Market Drivers
16. Brain Cancer Market Barriers
17. Brain Cancer Appendix
18. Brain Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/